NeOnc Technologies Holdings, Inc. (NTHI)
Nasdaq · Healthcare · Biotechnology
$2.92−2.34%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $84.1M
- 52-week range
- $2.88 – $12.99
- 52-week change
- −75.27%
- EPS (trailing)
- −$2.13
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $40K (−51.82%)
- Net income
- −$62.1M
- Operating margin
- −145636.4%
- Diluted EPS
- −$3.20
- Free cash flow
- −$20.9M
From the company’s annual report on SEC EDGAR.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Headquarters: Calabasas, United States · 5 employees · neonc.com